Genmab launches new case against Janssen, demands compensation and royalties

Despite recently losing a court case against US-based Janssen concerning milestone payments for cancer drug Darzalex Faspro, the Danish firm is now initiating new arbitration.
Photo: Genmab/PR
Photo: Genmab/PR
by marketwire, translated by catherine brett

Danish biotech firm Genmab has commenced new arbitration against its US-based partner Janssen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading